Remember for a second. la], for you to read.

In this world, countless things happen every day. Net.

These things may be a family, even a small thing that happens to an individual, or it may be a major event that affects a group, a city, or even a country!

Of course, even the so-called big things are for different people.

For example, if there is a coup d'état in a small country in Africa, this is definitely a big event for the people of this country, or the people of neighboring countries, but for people in the United States and China, it is a trivial matter that is not painful, and it is not even as important as what to eat at night!

The same is true of the two articles published by Tian Lu.

An ordinary person only cares about political news, entertainment news, or daily oil, salt, sauce and vinegar, unless it is really themselves or their family members who are sick, they will never care who is a cardiologist and who is a respiratory disease expert, for them, these are things that are far away from themselves. Of course, for the latest research progress in the medical field, they find it boring and boring, and they don't even bother to learn about it.

Even ordinary doctors, or researchers in other specialties, they don't care, and even most neurologists and neurosurgeons don't take a look. These clinicians will only care about technologies that can be put into practice and can be used on patients.

The only people who will really read these two articles and be shocked or rejoiced by these two articles are only a small group of people in the field of neuromedicine, even a very small part of all the practitioners of neuromedicine!

It's in this crowd. Tian Lu's two articles suddenly set off a storm!

Basically, everyone still remembers those three articles from more than two years ago, and once rejoiced at them, and after seeing this research report, this joy exploded again more than two years later! Almost every professional who reads this article can't help but pick up the phone at hand and can't wait to call their colleagues, friends, and share their excitement with them......

Of course. There is another group of people who are also shocked by this article, but they look at the problem from a different perspective than ordinary researchers. What they see is not the advancement of technology. And the dawn of countless neurological diseases being cured or controlled, in their eyes, what they see is a green dollar. Strong business opportunities!

These people, of course, are the multinational giants that make drugs!

The pharmaceutical industry is a special industry.

This is an industry that is a matter of human life, in the research and development of new drugs, such as the United States, Europe and other places, there is a very strict new drug listing system, each product from research and development, preclinical experiments, to clinical trials, and finally into clinical use, often requires more than a billion dollars. More than ten years, the development cycle is long, and the research and development cost is huge. So in the United States, there are generally only one or two dozen new drugs on the market every year, and these new drugs are on the market. All of them have become one of the most important products of various enterprises.

However, the pharmaceutical industry is also a highly profitable one.

Those multinational pharmaceutical giants, if they have a large number of patented drugs in their hands, then it means a steady stream of sales profits, not only the company's annual sales are extremely considerable, and even the annual investment in research and development is as high as billions of dollars.

And a top pharmaceutical company. Its core competitiveness is the patented drug in its hands!

Unlike generic drugs that flood the domestic market, the patented drugs in the hands of multinational giants are all lucrative products, and some commonly used drugs even sell billions of dollars every year. The most typical example is the world's No. 1 Ruihui, which is known as the "most profitable patented drug" Lipitor, with annual sales of more than 10 billion US dollars, and has been the world's number one best-selling drug for several consecutive years.

However, even among the multinational giants, not every drug is particularly profitable, and invention patents only have a 20-year protection period. Despite the patent compensation term system, in recent years, multinational pharmaceutical giants have ushered in the expiration of patent protection for original drugs, standing on the edge of the "patent cliff".

A large number of patent patents of fist products have expired or are about to expire, and multinational pharmaceutical companies are facing the threat of plummeting sales and declining profits. For example, after the expiration of the patented drug Lipitor, generic drugs were put on sale as soon as possible, which made Ruihui, the boss of the pharmaceutical industry, suffer heavy losses!

In order to cope with the expiration of this patented drug, multinational giants have focused more on the research and development of new drugs, in addition to establishing joint ventures in other countries to produce generic drugs to reduce losses. Basically, each of the world's top multinational pharmaceutical companies invests billions of dollars in research and development every year, and the No. 1 Pfizer has invested more than $70 billion in a decade in an attempt to find an alternative to Lipitor.

However, the investment in the research and development of new drugs is huge, and the success rate is extremely low.

The process of new drug research and development can be divided into two stages: research and development. The research stage determines the drug candidates, and the development stage can be divided into preclinical experiments and clinical trials. However, according to one statistic, for every 5,000 compounds evaluated, only five will have a chance to enter clinical trials, and only one of them will be approved for marketing in the end!

Every year, those multinationals start dozens of drug developments, and at the same time stop dozens of drug developments, and once a new drug is approved for marketing, it brings a steady stream of profits.

And it was Tian Lu's article that made many companies see the opportunity!

Central nervous system drugs are now a booming market, with a total global sales of hundreds of billions of dollars every year, so if the small molecule compound discovered by Tian Lu can finally successfully enter the clinic, its value can be imagined......

The United States, the headquarters of the multinational pharmaceutical giant Nofi.

In the vice president's office, Lossis held the magazine in his hand, staring at the name on the paper, Lossis bit his lip hard, and at this time he wanted to crash into the snow-white wall in his heart!

"If only I had driven higher!"

Although it has been a long time, when the director of the company's intelligence department showed him the latest "Nature" in the morning, the moment Lossis saw the author's name, he still remembered the young Chinese man who refused him without hesitation!

As one of the directions that Novi has focused on in recent years, central nervous system drugs have begun to occupy a higher and higher proportion in the company's total sales, especially Parkinson's and Alzheimer's drugs, which have grown very rapidly, and can be said to be the direction in which Novi has invested the most in recent years.

It's just that although the investment is huge, the results are unsatisfactory.

After all, Nofi's traditional advantage is tumor drugs, although it is investing more and more in central nervous system drugs, but compared with the other three or four strong companies, the gap is still relatively large, which is one of the reasons why Lossis would offer such high conditions to invite Tian Lu.

However, he now finds that the conditions for driving at the beginning were still too low!

A compound that can close the blood-brain barrier, for the time being, is absolutely unique in the world, that is, unlike other drugs, once this compound can be successfully marketed, then it will not have any competitors!

Everyone understands that monopoly is the most profitable.

Thinking of this, one of Lossis's hearts became more and more hot, and a pair of studies involuntarily placed on the name......

Not only is Nofi a company, nor is it just a senior executive of Losis, after Tian Lu's article was published, almost all multinational pharmaceutical giants got this issue of Nature magazine.

Able to grow to the level of multinational giants, these pharmaceutical companies are extremely concerned about the latest research developments in their disciplines while focusing on their own research and development. So basically every company has a special intelligence department, almost all high-quality academic journals, and every issue has someone to research, analyze, and try to find news that is beneficial to their company.

Businessmen are far more sensitive than those professional scholars.

While the researchers were still immersed in surprise, the multinational giants had long set their sights on the small molecule compound, on the author of the article.

Except for a few companies that have never been involved in central nervous system drugs, almost all multinational giants have made a decision at the first time: contact this Chinese scholar named Tian Lu to learn about this small molecule compound, if it does have clinical value, then you must get it at any cost!

Everyone understands the value of this small molecule compound.

With the improvement of the blood-brain barrier theory and the development of various cutting-edge research, it is conceivable that many mental diseases and senile diseases that could not be treated before will have the possibility of being cured or controlled, and with this, the sales of central nervous system drugs will definitely rise further in the future!

In the face of such a huge market, this small molecule compound that can close stress and open the blood-brain barrier can not be said to be as amazing as Lipitor, but it is absolutely no problem to become the flagship product of a company!

Stimulated by this obvious prospect, the aspiring multinational giants moved almost at the same time, and immediately issued instructions to the branch of Huaguo: to learn all the information about the Institute of Neurobiology of Beijing Normal University and verify all the information of that Tianlu.

To download the latest txt e-book of this book, please click:

This book is read on mobile phones:

Post a Review:

In order to facilitate the next reading, you can click on the "Collection" below to record the reading record of this time (Chapter 186 The Restlessness of the Multinational Giants), and you can see it next time you open the bookshelf! Please recommend this book to your friends (QQ, blog, WeChat, etc.), thank you for your support!!